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Introduction
Severe liver dysfunction with jaundice in late pregnancy is
an unusual and important event, because it can progress
very rapidly to fulminating status and mortality. The
major causes of liver dysfunction with jaundice are
acute viral hepatitis, acute fatty liver of pregnancy, 
tetracycline-induced liver damage, preeclampsia-related
liver disease, and “HELLP”. Among them, there are lim-
ited data available on the frequency, clinical outcome,
or vertical transmission rate of acute hepatitis C virus
(HCV) infection with jaundice during pregnancy in the
medical literature [1–5]. Here, we present a patient with
acute HCV infection and jaundice during pregnancy.
Case Report
A 27-year-old pregnant woman, gravida 2, para 1, with
gestational age of 36 weeks and 5 days, was referred 
to our hospital due to jaundice and elevated liver
enzymes without identified causes. She had been suffer-
ing from general weakness, lassitude, diarrhea and
occasional vomiting for 1 week, and jaundice with tea-
colored urine for about 3 days. Her past medical history
was unremarkable and she denied alcohol consumption
or smoking, needle-stick injury, history of recent multi-
ple transfusion, and history of intravenous drug abuse.
There was no evidence of preeclampsia, since no hyper-
tension (blood pressure 105/62 mmHg) was noted in the
outpatient department. Laboratory examinations during
admission (36 weeks and 5 days) showed white blood
cell count of 8.3109/L, hemoglobin 114 g/L, PT/
APTT 12 seconds (control 12.35 seconds)/25.4 seconds
(control 28.2 seconds), glucose (AC) 93 mg/dL, GOT/
GPT 599/811 U/L, bilirubin total/direct 6.4/5.7 mg/dL,
alkaline phosphatase 224 U/L, and LDH 321 U/L.
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SUMMARY
Objective: Acute viral hepatitis C-induced jaundice in pregnancy is very rare and may be fatal. Here, we report a
complicated case with acute hepatitis C-induced jaundice in pregnancy with successful management.
Case Report: A 27-year-old pregnant woman, gravida 2, para 1, with gestational age of 36 weeks and 5 days,
was referred to our hospital due to jaundice and elevated liver enzymes of undetermined cause. She had been
suffering from general weakness, diarrhea and vomiting for 1 week, and jaundice with tea-colored urine for 
3 days. At our medical center, acute viral hepatitis C-induced jaundice was suspected. Since her general condition
deteriorated at 36 weeks and 6 days of gestation, we decided to induce labor. A male baby was born smoothly
via the vaginal route, with birth weight 2,857 g, birth length 48.6 cm, and 1- and 5-minute Apgar scores of 
7 and 9, respectively. Maternal condition improved dramatically after delivery and her serum liver enzymes and
bilirubin levels gradually approached normal ranges.
Conclusion: Mothers and fetuses with acute viral hepatitis C-induced jaundice during pregnancy are at great
risk of mortality and morbidity. Timely termination may be one of the choices of treatment when fetal maturity
has been reached and the maternal condition has deteriorated. [Taiwanese J Obstet Gynecol 2006;45(2):180–182]
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■ SHORT COMMUNICATION ■
Abdominal ultrasonography showed normal liver
parenchymal echopattern without cholestasis. The radio-
immunoassay of serology showed hepatitis B surface
antigen (HBsAg) negative, hepatitis B envelope antigen
(HBeAg) negative, hepatitis A viral immunoglobin-M
(HAV-IgM) negative, and HCV antibody (HCV Ab) trace.
Therefore, acute hepatitis C with jaundice in pregnancy
was suspected.
Unfortunately, maternal general condition on the 2nd
day of admission (36 weeks and 6 days) showed remark-
able deterioration. Her laboratory data did not show
any improvement (Figure). After taking the fetal and
maternal risks into consideration for ongoing preg-
nancy, induction of labor with PGE1 was undertaken.
A male baby was born smoothly via the vaginal route at
36 weeks and 6 days, with birth weight of 2,857 g, birth
length of 48.6 cm, and 1- and 5-minute Apgar scores of
7 and 9, respectively. Dramatically, maternal condition
improved after delivery and the patient was discharged
3 days later.
Serologic HCV antibody titer at 3 weeks postpartum
showed 28 times elevation compared with the original
data during the 1st day of admission (HCV antibody:
trace). In contrast, at 2 months postpartum, both se-
rum GOT and bilirubin levels fell gradually to approach
normal ranges, with GOT/GPT 47/107 U/L (normal,
5–40/5–55 U/L) and bilirubin-total 0.9 mg/dL (normal,
0.2–1.4 mg/dL).
Discussion
Mothers and fetuses with acute HCV-induced jaundice
during pregnancy are at great risk of maternal mortality
and morbidity. Common causes of maternal death with
jaundice in pregnancy are hepatic failure and post-
partum hemorrhage due to coagulation failure [6].
Although acute viral hepatitis (AVH) is the most com-
mon cause of jaundice in pregnancy, HCV-induced jaun-
dice is extremely rare. Khuroo and Kamili [6] reported
that among AVH in pregnant women, the incidences of
viral hepatitis A, B, C, D, E, and non-A-to-E (HNAE)
were 1.5, 15, 1.7, 1.5, 49.6, and 30.7%, respectively.
Distinguishing the various types of viral hepatitis requires
not only a detailed history with risk stratification, but
also appropriate serologic marker follow-up.
The differential diagnoses for jaundice in pregnancy
include (1) intrahepatic cholestasis of pregnancy, (2)
preeclampsia with liver involvement, (3) cholecystitis,
(4) cholangitis, (5) alcohol, (6) drug or (7) acute fatty
liver of pregnancy (AFLP). In this patient, intrahepatic
cholestasis of pregnancy was excluded due to a normal
abdominal liver ultrasound. Preeclampsia with liver
involvement was excluded due to normal blood pres-
sure. Cholecystitis or cholangitis were excluded by nor-
mal physical palpation and normal liver sonography.
Alcohol- or drug-induced hepatitis were excluded since
she did not have any history of alcohol or drug abuse.
Further, it is important to differentiate between
severe AVH and AFLP for the following reasons: firstly,
treatment options may be different, as prompt termina-
tion of pregnancy is usually required for improving
prognosis in AFLP [7]; secondly, long-term prognosis
may be different in both groups, with some reports sug-
gesting that AFLP would recur in subsequent pregnan-
cies [8]. From the evolution of serum titers of HCV
antibody in this patient, the slow rise in HCV antibody
titer favors the diagnosis of HCV infection rather than
AFLP. Given the above analysis, the etiology of jaundice
in this patient is HCV infection.
For chronic hepatitis C infection without pregnancy,
combination therapy with interferon  plus ribavirin is
currently considered the standard treatment for patients
with chronic hepatitis C [9]. However, regarding the
risk to the fetus, ribavirin is categorized as X due to its
teratogenic effects in an animal model, and interferon
is categorized as C [9]. Therefore, for chronic hepatitis
C infection in pregnancy, combination therapy with
interferon  plus ribavirin is not recommended. In this
patient, the status of hepatitis C viral infection is acute
rather than chronic, thus, combination therapy with
interferon  plus ribavirin was not considered.
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Figure. After delivery, the maternal general condition
improved and liver enzymes began to fall. Therefore, the
patient was discharged 3 days postpartum. GOTglutamic
oxaloacetic transaminase; GPTglutamic pyruvic transami-
nase; Bil-Tbilirubin-total; Bil-Dbilirubin-direct ;  D–11
day before delivery; D0delivery day; D+11st day postpar-
tum; D+33rd day postpartum.
Nevertheless, for acute hepatitis C infection without
pregnancy, interferon  is often recommended. In a
review of therapy of acute hepatitis C infection without
pregnancy, Fried and Hoofnagle [10] concluded that
although the efficacy of interferon  in acute hepatitis
C has not been demonstrated, it is the only treatment we
have to date. In 1997, the National Institutes of Health
Consensus Panel of the United States concluded that
all patients with acute hepatitis C should be treated
with interferon  [11]. Two recent reviews [12,13]
reported on interferon treatment for HCV-positive
pregnant women, including those with hematologic dis-
orders; there were no abortions or fetal malformations
in any case where interferon was used. Based on the
available information, in patients with acute HCV infec-
tion during pregnancy, the use of interferon therapy
may be considered with close monitoring.
Perinatal mortality in maternal AVH with jaundice
may be as high as 25–75%, mostly due to prematurity
and intrauterine death, especially when postpartum
hemorrhage and coagulation failure occur [14]. In this
case, we decided to terminate pregnancy due to the
advanced fetal age (36 weeks and 6 days of gestation)
and the progressively deteriorating maternal condition.
From this case report, we learned that timely termination
may be one of the treatment choices when fetal maturity
is reached and maternal condition is deteriorating.
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